These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1611113)

  • 1. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin.
    Ferrari P; Castagnetti G; Pollastri CA; Ferrari G; Tavoni F; Grassi D
    Anticancer Drugs; 1992 May; 3 Suppl 1():25-7. PubMed ID: 1611113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
    Raitanen MP; Lukkarinen O
    Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
    Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
    Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
    Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.
    Rajala P; Liukkonen T; Raitanen M; Rintala E; Kaasinen E; Helle M; Lukkarinen O
    J Urol; 1999 Apr; 161(4):1133-5; discussion 1135-6. PubMed ID: 10081854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results.
    Rajala P; Kaasinen E; Raitanen M; Liukkonen T; Rintala E;
    J Urol; 2002 Sep; 168(3):981-5. PubMed ID: 12187204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study comparing different dose levels and administration schedules of interferon-alpha 2b combined with epirubicin for prevention of recurrence in bladder cancer.
    Serretta V; Pavone C; Corselli G; Pavone-Macaluso M
    Anticancer Drugs; 1992 May; 3 Suppl 1():19-23. PubMed ID: 1611112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
    Uekado Y; Hirano A; Shinka T; Ohkawa T
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
    Serretta V; Corselli G; Piazza B; Lio D; Gervasi F; Salerno S; Pavone-Macaluso M
    Urol Res; 1993; 21(5):353-7. PubMed ID: 8279093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical epirubicin in the prophylaxis of superficial bladder cancer.
    Sengör F; Beysel M; Erdoğan K; Erol A; Tuzluoğlu D
    Int Urol Nephrol; 1996; 28(2):201-6. PubMed ID: 8836789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
    Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
    Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
    Mitsumori K; Tsuchiya N; Habuchi T; Li Z; Akao T; Ohyama C; Sato K; Kato T
    BJU Int; 2004 Aug; 94(3):317-21. PubMed ID: 15291859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
    Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
    Boccardo F; Cannata D; Rubagotti A; Guarneri D; Decensi A; Canobbio L; Curotto A; Martorana G; Pegoraro C; Selvaggi F
    J Clin Oncol; 1994 Jan; 12(1):7-13. PubMed ID: 8270987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical epirubicin treatment following TUR in superficial bladder tumours.
    Imamoğlu MA; Bakirtaş H; Yiğitbaşi O; Ersoy H; Sertçelik AN
    Arch Esp Urol; 2001 Dec; 54(10):1147-53. PubMed ID: 11852530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, randomized trial to evaluate high-versus low-dose interferon-alpha 2b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder.
    Hoeltl W; Hasun R; Albrecht W
    Anticancer Drugs; 1992 May; 3 Suppl 1():29-32. PubMed ID: 1611114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of interferon-alpha-2b in the prevention of superficial carcinoma of the bladder recurrence.
    Mohanty NK; Gulati P; Saxena S
    Urol Int; 1997; 59(3):194-6. PubMed ID: 9428441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin: a review of its intravesical use in superficial bladder cancer.
    Onrust SV; Wiseman LR; Goa KL
    Drugs Aging; 1999 Oct; 15(4):307-33. PubMed ID: 10582777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
    Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.